Company Overview and News
Danaher Corporation (DHR - Free Report) is set to release third-quarter 2018 results on Oct 18, before the market opens. The company reported better-than-expected results in the last four quarters, pulling off an average positive earnings surprise of 4.95%. In the last reported quarter, the company’s earnings of $1.15 per share were above the Zacks Consensus Estimate of $1.09. In the past three months, the company’s shares have increased 2.
RXN TTEK CTRL DHR FLS
VANCOUVER, BC / ACCESSWIRE / October 16, 2018 / Prophecy Development Corp. ("Prophecy" or the "Company") (TSX:PCY, OTCQX:PRPCF, Frankfurt:1P2N) is pleased to announce that the Company has executed a lease agreement (the "Lease") with an arms-length private Mongolian company (the "Lessee") whereby the Lessee plans to perform mining operations at Prophecy's Ulaan Ovoo coal mine, and will pay Prophecy US$2 (the "Production Royalty") for every tonne of coal shipped from the Ulaan Ovoo site premises.
TTEK PRPCF PCY
WHITE ROCK, BC / ACCESSWIRE / October 15, 2018 / AZARGA METALS CORP. ("Azarga Metals" or the "Company") (TSX-V: AZR) has filed a technical report titled "Technical Report and Preliminary Economic Assessment for the Unkur Copper-Silver Project, Kodar-Udokan, Russian Federation" dated effective 30 August 2018 (the "Unkur PEA") for its Unkur Copper-Silver Project in Russia to support the Preliminary Economic Assessment announced on 30 and 31 August, 2018.
TTEK MALRY MALRF MIN
Dover Corporation (DOV - Free Report) is expected to report third-quarter 2018 results on Oct 18. In the last reported quarter, the company posted a positive earnings surprise of 7.4%. Notably, Dover surpassed the Zacks Consensus Estimate in each of the last four quarters, delivering an average surprise of 5.81%. Let’s see how things are shaping up prior to this announcement.
DOV.WI TTEK DOV FLS
2018-10-15 zacks - 1
Alcoa Corporation (AA - Free Report) is set to release third-quarter 2018 results on Oct 17, after the market closes. The company reported better-than-expected results in two of the last four quarters, while lagged estimates in two. The average four-quarter positive earnings surprise for the company is 5.79%. In the last reported quarter, Alcoa’s earnings of $1.52 per share surpassed the Zacks Consensus Estimate of $1.
AAI RXN TTEK AA FLS
W.W. Grainger, Inc. (GWW - Free Report) is expected to report third-quarter 2018 results on Oct 16, before the opening bell. Grainger surpassed the Zacks Consensus Estimate in each of the trailing four quarters, generating an average positive surprise of 21.47%. In the last reported quarter, it delivered a positive earnings surprise of 15.61%. Let’s see how things are shaping up for this announcement.
CBSH CBSHP GWW TTEK CBCB FLS
Century Aluminum Company’s (CENX - Free Report) full-owned subsidiary, Century Aluminum of South Carolina, Inc., has entered into an agreement with Santee Cooper that will enable the Goose Creek, SC plant to continue operating at half capacity. The agreement with Santee Cooper has a term till Dec 31, 2020. However, it can be terminated by Mt. Holly on a notice period of 120 days. Per the deal, Santee Cooper will continue to service 25% of the Mt.
Cohen & Steers (CNS - Free Report) reported preliminary assets under management (AUM) of $60.1 billion as of Sep 30, 2018, down 2% from the prior-month level. Market depreciation of $806 million and net outflows of $75 million and distributions of $333 million were the reasons for the decline. The company recorded total institutional accounts of $27.7 billion at the end of September, down 2.8% on a sequential basis.
CNS FII TTEK BEN IVZ
Offshore drillers Ensco plc (ESV - Free Report) and Rowan Companies plc (RDC - Free Report) have reached an agreement to merge in an all stock deal.The enterprise value of the combined entity is projected at $12 billion, based on the closing price of the companies’ shares on Oct 5, 2018. Terms of the Deal For each share held, Rowan shareholders will get 2.215 Ensco shares. On completion of the merger, Ensco and Rowan shareholders will own about 60.
DO TDGCF ATW RDC FCN ESV TTEK RIG PDS TDG SGAZF
The third quarter of this year proved to be an encouraging one for the U.S. apartment market with accelerating rent growth and increasing occupancy level. In fact, rents grew at an annual pace of 2.9% in the quarter and reversed the pattern of slowing price hikes since late 2015, per a study by the real estate technology and analytics firm — RealPage, Inc. (RP - Free Report) . Also, occupancy came in at 95.
UDR FCN EQR ESS TTEK RP AVB
WHITE SULPHUR SPRINGS, Mont., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Sandfire Resources America Inc. (“Sandfire America” or the “Company”) is pleased to provide the following update regarding activities related its underground Black Butte Copper project.
SRAFF SFRRF SNDFY TTEK SFR GNG
VANCOUVER, British Columbia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the “Company”) (TSX-V:CCB), (FF:U7N1) is pleased to announce the signing of a non-binding Memorandum of Understanding ("MOU") for the supply of the Company’s Miller nuclear purity graphite to Dunedin Energy Systems Ltd, an arm’s length Canadian developer of small modular nuclear reactors. The MOU terms are for the supply of 200 tonnes per annum of Miller nuclear purity graphite over a 10-year term, with a floor price of USD $40,000 per tonne.
HIE TTEK MALRY MALRF APR CCB APRLY MIN BRUZF
2018-09-18 proactiveinvestors.com.au - 1
Greenland Minerals Ltd (ASX:GGG) has conducted several engineering studies during a site visit to its Kvanefjeld Rare Earths Project in Greenland.
GGG TTEK 1800
We believe that Donaldson Company, Inc. (DCI - Free Report) is a solid choice for investors seeking exposure in the pollution control space. The stock, with roughly $7.4-billion market capitalization, has been upgraded to a Zacks Rank #1 (Strong Buy) on Sep 12. The company delivered better-than-expected results in two out of the last four quarters while lagging estimates in one and posting in-line results in one.
ADES TTEK ERII
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TTEK / Tetra Tech, Inc. on message board site Silicon Investor.
|Tetra Tech (TTEK)||Tetra Tech (TTEK)||Tetra Tech (TTEK)|
as of ET